How a Drug Company Made $114 Billion by Gaming the U.S. Patent System

Posted February 5th, 2023 by Brahm Canzer & filed under Company Analysis, Economic Analysis, Financial analysis, Financial Planning, Governments & Regulators, Growth & Valuation, Industry Analysis, Management Issues, Market Analysis, Personal Finance.

Description: AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end.

Source: NYTimes.com

Date: Jan 28, 2023

Link: https://www.nytimes.com/2023/01/28/business/humira-abbvie-monopoly.html

Questions for discussion:

Summarize the issues related to how businesses, governments, insurance companies and consumers are connected to the drug Humira.
Is this an acceptable system for the industry, in your opinion?
How might the system be changed in order to be more fair to all parties?